サマリー

Ustekinumabは、免疫・炎症反応に関与するサイトカインであるインターロイキン（IL）-12およびIL-23に対するヒト免疫グロブリン（Ig）G1カッパモノクローナル抗体です。

市場分析と洞察。世界および中国のUstekinumab市場
当レポートでは、Ustekinumabの世界および中国市場に焦点を当てています。
2020年のUstekinumabの世界市場規模はXX百万米ドルで、2021年から2027年の間にXX％のCAGRで、2027年末までにXX百万米ドルに達すると予想されています。中国では、Ustekinumabの市場規模は2020年のXX百万米ドルから2027年にはXX百万米ドルまで、予測期間中にXX％のCAGRで成長すると予測されています。

世界のUstekinumabの範囲と市場規模
Ustekinumabの市場は、地域（国）別、プレイヤー別、タイプ別、アプリケーション別に分類されています。世界のUstekinumab市場に参加するプレイヤー、ステークホルダー、その他の参加者は、本レポートを強力なリソースとして活用することで、優位に立つことができるでしょう。セグメント分析では、2016年から2027年までの地域（国）別、タイプ別、アプリケーション別の売上高と予測に焦点を当てています。
中国市場については、2016-2027年のUstekinumabの市場規模を、プレイヤー別、タイプ別、アプリケーション別に分析しています。主要プレイヤーには、中国で重要な役割を果たしているグローバルプレイヤーとローカルプレイヤーが含まれています。

タイプ別セグメント
静脈内投与
皮下投与

用途別セグメント
関節炎
大腸炎
エリテマトーデス（Lupus Erythematosus
手掌足底膿疱症を伴う多発性筋炎
肝硬変(Cirrhosis of the Liver)
サルコイドーシス
糖尿病
その他

地域別
北アメリカ
米国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
アジアパシフィック
中国
日本
韓国
インド
オーストラリア
台湾
インドネシア
タイ
マレーシア
フィリピン
ベトナム
ラテンアメリカ
メキシコ
ブラジル
アルゼンチン
中近東・アフリカ
トルコ
サウジアラビア
UAE

会社別
明治
ジョンソン・エンド・ジョンソン
アルボテック
富士フイルム
田辺三菱製薬
スタダ
EPIRUS BioPharma
フォーミーコン
NeuClone
アウトルック・セラピューティクス
ハーベストムーン・ファーマ
バイオエックスプレス

ページTOPに戻る

目次

1 Study Coverage
1.1 Ustekinumab Product Introduction
1.2 Market by Type
1.2.1 Global Ustekinumab Market Size Growth Rate by Type
1.2.2 Intravenous
1.2.3 Subcutaneous
1.3 Market by Application
1.3.1 Global Ustekinumab Market Size Growth Rate by Application
1.3.2 Arthritis
1.3.3 Colitis
1.3.4 Lupus Erythematosus
1.3.5 Myositis Multiplex With Palmoplantar Pustulosis
1.3.6 Cirrhosis Of The Liver
1.3.7 Sarcoidosis
1.3.8 Diabetes
1.3.9 Other
1.4 Study Objectives
1.5 Years Considered

2 Executive Summary
2.1 Global Ustekinumab Market Size, Estimates and Forecasts
2.1.1 Global Ustekinumab Revenue 2016-2027
2.1.2 Global Ustekinumab Sales 2016-2027
2.2 Global Ustekinumab, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Ustekinumab Historical Market Size by Region (2016-2021)
2.3.1 Global Ustekinumab Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Ustekinumab Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Ustekinumab Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Ustekinumab Sales Forecast by Region (2022-2027)
2.4.2 Global Ustekinumab Revenue Forecast by Region (2022-2027)

3 Global Ustekinumab Competitor Landscape by Players
3.1 Global Top Ustekinumab Manufacturers by Sales
3.1.1 Global Ustekinumab Sales by Manufacturer (2016-2021)
3.1.2 Global Ustekinumab Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Ustekinumab Manufacturers by Revenue
3.2.1 Key Ustekinumab Manufacturers Covered: Ranking by Revenue
3.2.2 Global Ustekinumab Revenue by Manufacturers (2016-2021)
3.2.3 Global Ustekinumab Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Ustekinumab Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Ustekinumab Revenue in 2020
3.2.6 Global Ustekinumab Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Ustekinumab Price by Manufacturers
3.4 Global Ustekinumab Manufacturing Base Distribution, Product Types
3.4.1 Ustekinumab Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Ustekinumab Product Type
3.4.3 Date of International Manufacturers Enter into Ustekinumab Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2016-2027)
4.1 Global Ustekinumab Market Size by Type (2016-2021)
4.1.1 Global Ustekinumab Sales by Type (2016-2021)
4.1.2 Global Ustekinumab Revenue by Type (2016-2021)
4.1.3 Ustekinumab Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Ustekinumab Market Size Forecast by Type (2022-2027)
4.2.1 Global Ustekinumab Sales Forecast by Type (2022-2027)
4.2.2 Global Ustekinumab Revenue Forecast by Type (2022-2027)
4.2.3 Ustekinumab Average Selling Price (ASP) Forecast by Type (2022-2027)

5 Breakdown Data by Application (2016-2027)
5.1 Global Ustekinumab Market Size by Application (2016-2021)
5.1.1 Global Ustekinumab Sales by Application (2016-2021)
5.1.2 Global Ustekinumab Revenue by Application (2016-2021)
5.1.3 Ustekinumab Price by Application (2016-2021)
5.2 Ustekinumab Market Size Forecast by Application (2022-2027)
5.2.1 Global Ustekinumab Sales Forecast by Application (2022-2027)
5.2.2 Global Ustekinumab Revenue Forecast by Application (2022-2027)
5.2.3 Global Ustekinumab Price Forecast by Application (2022-2027)

6 China by Players, Type and Application
6.1 China Ustekinumab Market Size YoY Growth 2016-2027
6.1.1 China Ustekinumab Sales YoY Growth 2016-2027
6.1.2 China Ustekinumab Revenue YoY Growth 2016-2027
6.1.3 China Ustekinumab Market Share in Global Market 2016-2027
6.2 China Ustekinumab Market Size by Players (International and Local Players)
6.2.1 China Top Ustekinumab Players by Sales (2016-2021)
6.2.2 China Top Ustekinumab Players by Revenue (2016-2021)
6.3 China Ustekinumab Historic Market Review by Type (2016-2021)
6.3.1 China Ustekinumab Sales Market Share by Type (2016-2021)
6.3.2 China Ustekinumab Revenue Market Share by Type (2016-2021)
6.3.3 China Ustekinumab Price by Type (2016-2021)
6.4 China Ustekinumab Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Ustekinumab Sales Forecast by Type (2022-2027)
6.4.2 China Ustekinumab Revenue Forecast by Type (2022-2027)
6.4.3 China Ustekinumab Price Forecast by Type (2022-2027)
6.5 China Ustekinumab Historic Market Review by Application (2016-2021)
6.5.1 China Ustekinumab Sales Market Share by Application (2016-2021)
6.5.2 China Ustekinumab Revenue Market Share by Application (2016-2021)
6.5.3 China Ustekinumab Price by Application (2016-2021)
6.6 China Ustekinumab Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Ustekinumab Sales Forecast by Application (2022-2027)
6.6.2 China Ustekinumab Revenue Forecast by Application (2022-2027)
6.6.3 China Ustekinumab Price Forecast by Application (2022-2027)

7 North America
7.1 North America Ustekinumab Market Size YoY Growth 2016-2027
7.2 North America Ustekinumab Market Facts & Figures by Country
7.2.1 North America Ustekinumab Sales by Country (2016-2021)
7.2.2 North America Ustekinumab Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada

8 Asia Pacific
8.1 Asia Pacific Ustekinumab Market Size YoY Growth 2016-2027
8.2 Asia Pacific Ustekinumab Market Facts & Figures by Region
8.2.1 Asia Pacific Ustekinumab Sales by Region (2016-2021)
8.2.2 Asia Pacific Ustekinumab Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
8.2.12 Philippines
8.2.13 Vietnam

9 Europe
9.1 Europe Ustekinumab Market Size YoY Growth 2016-2027
9.2 Europe Ustekinumab Market Facts & Figures by Country
9.2.1 Europe Ustekinumab Sales by Country (2016-2021)
9.2.2 Europe Ustekinumab Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy

10 Latin America
10.1 Latin America Ustekinumab Market Size YoY Growth 2016-2027
10.2 Latin America Ustekinumab Market Facts & Figures by Country
10.2.1 Latin America Ustekinumab Sales by Country (2016-2021)
10.2.2 Latin America Ustekinumab Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina

11 Middle East and Africa
11.1 Middle East and Africa Ustekinumab Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Ustekinumab Market Facts & Figures by Country
11.2.1 Middle East and Africa Ustekinumab Sales by Country (2016-2021)
11.2.2 Middle East and Africa Ustekinumab Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 UAE

12 Company Profiles
12.1 Meiji
12.1.1 Meiji Corporation Information
12.1.2 Meiji Description and Business Overview
12.1.3 Meiji Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Meiji Ustekinumab Products Offered
12.1.5 Meiji Recent Development
12.2 Johnson & Johnson
12.2.1 Johnson & Johnson Corporation Information
12.2.2 Johnson & Johnson Description and Business Overview
12.2.3 Johnson & Johnson Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Johnson & Johnson Ustekinumab Products Offered
12.2.5 Johnson & Johnson Recent Development
12.3 Alvotech
12.3.1 Alvotech Corporation Information
12.3.2 Alvotech Description and Business Overview
12.3.3 Alvotech Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Alvotech Ustekinumab Products Offered
12.3.5 Alvotech Recent Development
12.4 Fuji Pharma
12.4.1 Fuji Pharma Corporation Information
12.4.2 Fuji Pharma Description and Business Overview
12.4.3 Fuji Pharma Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Fuji Pharma Ustekinumab Products Offered
12.4.5 Fuji Pharma Recent Development
12.5 Mitsubishi Tanabe
12.5.1 Mitsubishi Tanabe Corporation Information
12.5.2 Mitsubishi Tanabe Description and Business Overview
12.5.3 Mitsubishi Tanabe Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Mitsubishi Tanabe Ustekinumab Products Offered
12.5.5 Mitsubishi Tanabe Recent Development
12.6 Stada
12.6.1 Stada Corporation Information
12.6.2 Stada Description and Business Overview
12.6.3 Stada Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.6.4 Stada Ustekinumab Products Offered
12.6.5 Stada Recent Development
12.7 EPIRUS BioPharma
12.7.1 EPIRUS BioPharma Corporation Information
12.7.2 EPIRUS BioPharma Description and Business Overview
12.7.3 EPIRUS BioPharma Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.7.4 EPIRUS BioPharma Ustekinumab Products Offered
12.7.5 EPIRUS BioPharma Recent Development
12.8 Formycon
12.8.1 Formycon Corporation Information
12.8.2 Formycon Description and Business Overview
12.8.3 Formycon Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Formycon Ustekinumab Products Offered
12.8.5 Formycon Recent Development
12.9 NeuClone
12.9.1 NeuClone Corporation Information
12.9.2 NeuClone Description and Business Overview
12.9.3 NeuClone Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.9.4 NeuClone Ustekinumab Products Offered
12.9.5 NeuClone Recent Development
12.10 Outlook Therapeutics
12.10.1 Outlook Therapeutics Corporation Information
12.10.2 Outlook Therapeutics Description and Business Overview
12.10.3 Outlook Therapeutics Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.10.4 Outlook Therapeutics Ustekinumab Products Offered
12.10.5 Outlook Therapeutics Recent Development
12.11 Meiji
12.11.1 Meiji Corporation Information
12.11.2 Meiji Description and Business Overview
12.11.3 Meiji Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Meiji Ustekinumab Products Offered
12.11.5 Meiji Recent Development
12.12 BioXpress
12.12.1 BioXpress Corporation Information
12.12.2 BioXpress Description and Business Overview
12.12.3 BioXpress Ustekinumab Sales, Revenue and Gross Margin (2016-2021)
12.12.4 BioXpress Products Offered
12.12.5 BioXpress Recent Development

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Ustekinumab Industry Trends
13.2 Ustekinumab Market Drivers
13.3 Ustekinumab Market Challenges
13.4 Ustekinumab Market Restraints

14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Ustekinumab Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer